Hydrogen gas inhalation therapy may not work sufficiently to mitigate oxidative stress induced with REBOA.
Yosuke Matsumura, Yosuke Hayashi, Makoto Aoki, Yoshimitsu Izawa · Scientific reports · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In an animal model, hydrogen gas inhalation therapy exhibited no significant difference compared to the control group in survival, lactate level, 8-OHdG, and intestinal mucosal injury following REBOA in a hemorrhagic shock model. These preclinical findings add evidence about the molecular-hydrogen effects, outcomes, and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen was evaluated in this publication and summarizes the source-grounded findings below. Hydrogen gas inhalation therapy exhibited no significant difference compared to the control group in survival, lactate level, 8-OHdG, and intestinal mucosal injury following REBOA in a hemorrhagic shock model.
What the Researchers Studied
The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 2% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 2% source-reported H₂ gas concentration. Hydrogen gas inhalation therapy exhibited no significant difference compared to the control group in survival, lactate level, 8-OHdG, and intestinal mucosal injury following REBOA in a hemorrhagic shock model. Unlike other oxidative stress pathologies, hydrogen gas inhalation therapy may not work sufficiently to alleviate systemic oxidative stress in REBOA-IRI.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The reported sample size was 10. The study used a preclinical animal experiment. The source-reported hydrogen concentration was 2% source-reported H₂ gas concentration.
Limitations and Safety
Reported limitations: Despite these limitations, future research in hydrogen gas inhalation is warranted to accumulate scientific evidence in REBOA-IRI for safety and feasibility. Safety information: No adverse events related to the hydrogen gas inhalation were observed in the experimental period.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.